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Translational Relevance
PI3 kinase delta is a critical molecule in B-cell receptor (BCR) pathway which is responsible for survival, proliferation, and maintenance of healthy and malignant B-cells. Both in preclinical and clinical studies idelalisib-a PI3 kinase delta-specific inhibitor showed target inactivation and biological impact. In both settings, pharmacodynamic endpoint has generally focused on inhibition of PI3 and AKT kinases. Our study investigated downstream of PI3K/AKT axis in mantle cell lymphoma, a B-cell malignancy, to recognize molecules in the BCR network that are inhibited with idelalisib. We identified that global protein synthesis was consistently and significantly impacted, which is in concordance with deactivation of AKT, PRAS40 and MAPK oncogenic pathway. Specifically, MEK and downstream effector p90RSK phosphorylation levels were decreased. Inhibition of these pathways may provide mechanism-based combination strategy with idelalisib to extend its clinical usage in B-cell diseases. 
Introduction
Phosphoinositide-3-kinases (PI3Ks) are a family of kinases responsible for regulating multiple cellular functions and are signaling enzymes that mediate extracellular and intracellular signaling (1). PI3Ks are composed of three classes with overlapping but non-redundant functions. Class I members, the key players in human cancers, consist of heterodimers of a catalytic subunit (p110α, β and δ for class IA and γ for class IB) and a regulatory unit (p85 for class IA and p101 for class IB). The isoform p110δ (PI3Kδ) is highly expressed in the B-cell hematopoietic system and plays key roles in leukocyte signaling, proliferation and differentiation, as well as chemotaxis (1-3). PI3Kδ is unique and essential for B-cell receptor-mediated signaling, and PI3K is immediately activated when BCR binds with ligands (4-6).
Survival of healthy mature B-lymphocytes is dependent on the BCR signaling through Ig-heavy chain (7), and it has been shown that BCR network dependence is through PI3K signaling (8).
Loss of BCR or PI3K decreased life-span (9), generation and survival of these B-lymphocytes (10) . The connecting molecule between BCR and PI3K cassette in normal B-cells was Syk (11) .
In concert with PI3K, CD19 initiated signal transduction pathway (12) and MAPK down-stream cascade appear to be essential in mature B-lymphocyte development and maintenance (13) .
Finally, Ras-Raf-MAPK and PI3K-mTOR signaling, albeit in solid tumors, have been indicated to be primary nodes in tumorigenesis (14) . These key processes have been defined in normal (and not malignant) B-cell homeostasis and development.
PI3K helps transmit BCR signaling into the cytoplasmic space by activating various downstream signaling molecules through PDK1 and then AKT, followed by activation of cascades of kinases and phosphatases that ultimately promote the oncogenic phenotypes of malignant B-cells (15, Research.
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Protein expression analysis using immunoblots. Cells were lysed and protein contents were measured as described (38) . Total protein (30-50µg) were loaded onto 4-12% or 10% SDSpolyacrylamide gels and transferred to nitrocellulose membranes (GE Osmonics Labstore, Minnetonka, MN), and probed with various antibodies (Supplemental Table 3 ) (38). Infraredlabeled secondary antibodies (donkey anti-mouse, anti-rabbit or anti-goat, LI-COR Biosciences, Lincoln, NE) were used, allowing proteins of similar sizes to be visualized on the same immunoblot using a LI-COR Odyssey Infrared Imager, as described previously (38).
Data and statistical analyses. GraphPad Prism software was used to draw plots and perform the Student's paired t-tests. Linear models or linear mixed effects models were used to study the linear and quadratic effects of idelalisib after adjusting for fixed cell line effects or random primary MCL cell effects using the lm function or the lmer function (lme4 package) in R software. Multiple comparison of each concentration versus the DMSO control was performed using glht function (multcomp package) in R software. Phosphorylated and total protein levels detected via immunoblot analysis were quantified using LI-COR Image Studio Lite and were normalized to control. The ratios of phosphorylated to total protein levels or the ratios of protein to GAPDH/vinculin levels were calculated.
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Results

Idelalisib treatment decreased cell number and size and led to moderate levels of cell death in MCL cells
We first evaluated growth inhibition and cell-death induction by idelalisib. JeKo-1, Mino and Granta 519 were treated with DMSO or with 0.5μM or 5μM of idelalisib for 24 or 48h. Cell numbers decreased by 6-20% after 48h treatment, with statistically significant declines measured in JeKo-1 cells treated with 0.5μM idelalisib and in Mino and Granta 519 cells treated with 5μM idelalisib ( Figure 1A ). Nonetheless, the cytotoxicity effect is minor. In contrast, significant cell size changes (8-26% decrease) were detected in all cell lines ( Figure 1B ). JeKo-1 and Granta 519 cells seemed to be more responsive than Mino cells in cell number and cell size reductions.
Similar results were detected after 24h treatment (data not shown).
Despite the inhibition of cell growth, 48h treatment with idelalisib induced only moderate levels of apoptosis. Cell death levels of 5-10% were detected in cell lines ( Figure 1C ). In MCL patient samples (n=14), there were variable levels of apoptosis ( Figure 1D ). With a median of 38% endogenous cell death in the control cells (DMSO), which increased by 9%, 14%, 16% and 18% with 0.05, 0.3, 0.5 and 1μM idelalisib treatment, respectively. This moderate level of cell death is common with kinase inhibitors including idelalisib (20, 31, 32, 39, 40). At 5μM, apoptosis was not greater than measured with 1µM idelalisib ( Figure 1D ) which may reflect saturation of inhibition of PI3Kδ isoform with idelalisib (IC 50 in a biochemical assay is 19 nM) as well as >90% binding of drug to plasma proteins (5, 41).
Cellular autophagy levels were also measured in MCL cell lines, and a 16% induction of autophagy was detected in JeKo-1 cells treated with 0.05μM of idelalisib. Autophagy levels decreased with higher concentrations, with around 10% autophagy induced by 0.1 and 0.5μM idelalisib and 4% at 1 and 5μM ( Figure 1E ). Lower levels of autophagy were detected in Mino and Granta 519 cells, in which the highest autophagy levels was 5% with 0.1μM idelalisib in Mino and 8% with 0.5μM in Granta 519. Cell cycle profile changes were measured in MCL cell lines following 48h treatment with idelalisib (Supplemental Figure 1) . None of the cell lines showed any major difference in G1-, S-, or G2/M-percent population of the cell cycle after 48 hours of treatment with 0.5 and 5μM of idelalisib. .
Idelalisib treatment resulted in significant decreases in global protein synthesis in MCL cells
PI3Kα signaling affects regulation of transcription and translation processes in human cancers (34). By inhibiting the activity of PI3Kδ using idelalisib, we detected significant decreases of global protein synthesis in both cell lines and primary samples. There was a 15-60% decrease in protein synthesis levels after MCL cell lines were treated with 0.5μM idelalisib for 48h ( Figure   2A ). Consistent with the apoptosis and autophagy data, JeKo-1 showed the highest sensitivity to treatment (>50% decrease), followed by Granta 519 (>40% decrease) and then Mino cells (~15% decrease). Interestingly, a more significant decrease in protein synthesis was observed at 0.5μM than at 5μM in all three cell lines ( Figure 2A ). Of nine primary MCL patient samples, three treated with 5μM idelalisib had >30% reduction in protein synthesis after 24 h while the other six samples had greater inhibition (>50%) ( Figure 2B ).
Interestingly, idelalisib treatment did not consistently induce significant reductions in global RNA synthesis in MCL cells. In the three cell lines tested, only JeKo-1 had a ~15% decrease in RNA synthesis following 5μM idelalisib for 48h with no changes detected in the other cell lines ( Figure 2C ). Of nine MCL patient samples, three samples had no or slight decrease (up to 15%), three had a 30-40% decrease, and three showed a >50% decline in global RNA synthesis levels ( Figure 2D ).
Idelalisib treatment inhibited IgM-mediated activation of PI3K immediate downstream targets in MCL cells
To investigate the effects of idelalisib on PI3K signaling in BCR-activated MCL cells, MCL cell lines and primary cells from patients were serum starved (0.5% FBS) for 1h, then treated with DMSO or idelalisib for 1h, followed by 15min of anti-IgM stimulation to activate BCR signaling before harvest. In JeKo-1 and Granta 519 but not Mino cells, phosphorylation levels of AKT (activation sites Thr308) were enhanced following anti-IgM treatment ( Figure 3A) . Figure 3B . Phosphorylation of AKT (Thr308) was induced following anti-IgM stimulation in MCL primary samples tested; however, only a slight increase of phospho-PDK1 was detected ( Figure 3B ). All three MCL cell lines and primary samples (n=4) treated with different concentrations of idelalisib showed significant decreases in phosphorylation levels of AKT (Thr308), starting at 0.5μM concentration ( Figure 3C ). In contrast, phospho-PDK1 levels showed <25% decrease in both MCL cell lines and primary MCL samples ( Figure 3C) . Notably, the decrease in phosphorylation levels of PDK1 did not seem to be dose-dependent in either cell lines or primary cells ( Figure 3C ).
Downstream of AKT, following IgM stimulation, GSK-3β (Ser9) phosphorylation levels were induced in JeKo-1 and Mino but not in Granta 519 cells ( Figure 3A) . Similarly, primary samples showed increased phospho-GSK-3β levels with IgM co-incubation ( Figure 3B ). Phosphorylation 
Idelalisib treatment inhibited the activation of MAPK/MEK pathway protein translation regulators in MCL cells
Interestingly, MCL cell line data from reverse phase protein array (RPPA) suggested that in addition to the PI3K/AKT axis, the MAPK/MEK pathway was also impacted (data not shown).
To confirm these observations, we tested the changes of protein and their phosphorylation levels The phosphorylation levels of p90RSK (Thr359/Ser363) consistently increased following IgM stimulation in MCL lines and primary cells ( Figure 5A , 5B). In addition, both cell lines and primary cells exhibited robust responses to drug treatment, as phospho-p90RSK levels were decreased in all samples evaluated ( Figure 5C ).
Proteomics analyses confirmed PI3K/AKT and MAPK pathway inhibition by idelalisib in primary MCL cells
To further confirm the signaling pathway changes induced by idelalisib, a set of seven MCL primary samples was analyzed using RPPA after treatment with DMSO or 1μM of idelalisib for 24h ( Figures 6A, 6B, 6C ). Despite the inherit heterogeneity among patient samples, interestingly, it seems idelalisib treatment led to an increased expression of p85 subunit of PI3K in four patient samples, whereas p110α and β levels did not significantly increase to compensate for the loss of p110δ function. In fact, p110α levels were modestly decreased. Syk levels also appeared to be increased in most (5 out of 7) of the primary samples evaluated. Contrary to previous findings (42), there was no consistent loss of PTEN in these primary MCL cells ( Figure 6A ). Importantly, efficacy was higher at the recommended phase II dose of 150 mg twice/day (27). At this dose, pharmacokinetic investigations suggested that the plasma concentration of free drug was 2 to 6 µM (24). The pharmacodynamic endpoint, determined only in the study with CLL patients, demonstrated that compared with normal B-cells, malignant B-cells had higher constitutively active AKT (measured as phosphorylation at Thr308). This was mitigated after 8 days of idelalisib treatment and was sustained even after 28 days (24), however, the effect on targets downstream of AKT was not studied. These investigations were instrumental to the approval of idelalisib for these B-cell neoplasms (25, 26).
In the current study, we evaluated biological and molecular changes in MCL cells, specifically those involved in transcription and translation, the pathways established in PI3Kα investigations.
MCL was selected because this B-cell malignancy responded to idelalisib. Furthermore, genetically annotated cell lines (Supplemental Table 1 ) and primary MCL lymphocytes were available to validate these targets. Cell lines, rather than mature replicationally quiescent lymphocytes, were needed to investigate biological changes that focus on cell cycle, growth, and cell size effects. Using these model systems and idelalisib at physiologically relevant concentrations, we evaluated the changes in three cell lines and fourteen patient samples and detected significant and consistent inhibition of global protein synthesis with moderate growth inhibition and cell death (Figures 1, 2A, 2B ). Prior investigations in another B-cell malignancy Signal transduction through the PI3K, PDK1, and AKT nexus is not linear; rather represents a network. Two primary channels are the mTOR and MAPK axes; both these pathways at their termini impact protein translation. It is known that AKT is activated at Thr308 through PI3K
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pathway activation and interaction via PDK1 (46), and it is also activated by mTORC2 at the Ser473 residue (47). Our data showed that the AKT-Thr308 level generally decreased following idelalisib treatment (Figures 3, 6 shown as means ± SEM. Student's t-test was performed in Figure 1A , 1B, and 1C ; *P<0.05 and **P<0.01, respectively. Linear mixed effects model and linear model were performed for quadratic treatment effects in Figure 1D (MCL primary cells experiments) and 1E, respectively.
In Figure 1D , the idelalisib treatment resulted in a significant quadratic increase of cell death.
From multiple comparison, 0.5, 1, and 5µM idelalisib treatment resulted in statistically significant increases in cell death compared with DMSO control, while induction of autophagy levels ( Figure 1E ) did not result in a statistically significance increase, except for 5µM treatment in Mino cells, as indicated by the asterisk. 
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